PF-Atlas › Clinical Trials › NCT03221257

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Pirfenidone · Phase 2

Registry ID
NCT03221257
Phase
Phase 2
Status
Completed
Drug / intervention
Pirfenidone (PFD)
Sponsor
Michael Roth
Start
2017-11-28
Enrollment
51
Locations
16

About this trial

A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).

View NCT03221257 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT03221257 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.